Fiche publication
Date publication
juillet 2025
Journal
NEJM evidence
Auteurs
Membres identifiés du Cancéropôle Est :
Dr SIMAND Célestine
Tous les auteurs :
Hunault M, Pautas C, Bertoli S, Dumas PY, Raffoux E, Hospital MA, Marchand T, Heiblig M, Chantepie S, Carré M, Peterlin P, Gallego-Hernanz MP, Lemasle E, Guièze R, Simand C, Turlure P, Huynh A, Leguay T, Devillier R, Quoc SN, Duployez N, Luquet I, Penther D, Celli-Lebras K, Mineur A, Raus N, Gardin C, Socié G, Cahn JY, Ifrah N, Vey N, de Latour RP, Delabesse E, Preudhomme C, Hamel JF, Pigneux A, Récher C, Dombret H
Lien Pubmed
Résumé
We conducted a randomized controlled trial to compare intermediate doses (IDAC) with high doses of cytarabine (HDAC) as postinduction therapy in patients 18 to 60 years of age with newly diagnosed acute myeloid leukemia (AML). The main objectives were to evaluate noninferiority in overall survival (OS) after IDAC and safety.
Mots clés
Humans, Cytarabine, administration & dosage, Adult, Middle Aged, Leukemia, Myeloid, Acute, drug therapy, Male, Female, Young Adult, Adolescent, Antimetabolites, Antineoplastic, administration & dosage, Hematopoietic Stem Cell Transplantation, Treatment Outcome, Remission Induction
Référence
NEJM Evid. 2025 07;4(7):EVIDoa2400326
